Gilead Sciences (GILD) Deferred Taxes (2009 - 2026)

Gilead Sciences has reported Deferred Taxes for 18 years, with the latest figure at $179.0 million in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 189.95% year-over-year to $179.0 million; the trailing twelve-month figure through Mar 2026 stood at $538.0 million (up 140.76% YoY), and the FY2025 full-year result was $160.0 million, up 108.68% from the prior year.
• Deferred Taxes for Q1 2026 stood at $179.0 million, up from -$122.0 million in the prior quarter.
• The five-year high for Deferred Taxes was $659.0 million in Q3 2025, with the low at -$723.0 million in Q1 2024.
• Historically, Deferred Taxes has averaged -$236.4 million across 5 years, with a median of -$270.0 million in 2022.
• Annual changes were most pronounced in 2022 — Deferred Taxes tumbled 1016.9% — and 2025, when it surged 214.41%.
• Gilead Sciences' Deferred Taxes stood at -$338.0 million in 2022, then slipped by 9.47% to -$370.0 million in 2023, then retreated by 2.43% to -$379.0 million in 2024, then soared by 67.81% to -$122.0 million in 2025, then surged by 246.72% to $179.0 million in 2026.
• The last three Deferred Taxes figures came in at $179.0 million (Q1 2026), -$122.0 million (Q4 2025), and $659.0 million (Q3 2025), per Business Quant data.